1. Home
  2. DTF vs ACET Comparison

DTF vs ACET Comparison

Compare DTF & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DTF Tax-Free Income 2028 Term Fund Inc.

DTF

DTF Tax-Free Income 2028 Term Fund Inc.

HOLD

Current Price

$11.34

Market Cap

79.8M

Sector

Finance

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.52

Market Cap

71.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTF
ACET
Founded
1991
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.8M
71.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DTF
ACET
Price
$11.34
$0.52
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
21.1K
2.9M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
3.64%
N/A
EPS Growth
N/A
N/A
EPS
0.44
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.29
$0.45
52 Week High
$11.19
$1.11

Technical Indicators

Market Signals
Indicator
DTF
ACET
Relative Strength Index (RSI) 50.13 43.00
Support Level $11.33 $0.47
Resistance Level $11.40 $0.52
Average True Range (ATR) 0.06 0.04
MACD -0.00 0.01
Stochastic Oscillator 33.36 45.30

Price Performance

Historical Comparison
DTF
ACET

About DTF DTF Tax-Free Income 2028 Term Fund Inc.

DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: